
    
      ECLIPSE is a treatment, Phase 1 multicenter, prospective, single-arm study with participants
      serving as their own control. This study is to enroll participants who will undergo
      cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 cm.
      Participants will be followed for 5 years post their cryoablation procedure.

      Cryoablation is the process of destroying tissue by the application of extremely cold
      temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of
      general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung),
      Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal), and urology
      (kidney).
    
  